# Associations between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy, Tirzepetide vs. Dulaglutide or Semaglutide on major cardiovascular events in T2D, and more!

Page: https://stenobird.com/podcast/doc-updates-200053/associations-between-glp-1-receptor-agonists-and-ischemic-optic-neuropathy-tirzepetide-vs-dulaglutide-or-semaglutide-on-major-cardiovascular-events-in-t2d-and-more
Text version: https://stenobird.com/podcast/doc-updates-200053/associations-between-glp-1-receptor-agonists-and-ischemic-optic-neuropathy-tirzepetide-vs-dulaglutide-or-semaglutide-on-major-cardiovascular-events-in-t2d-and-more.md
Podcast: [DOC Updates](https://stenobird.com/podcast/doc-updates-200053)
Published: 2026-05-01T10:00:00+00:00
Episode link: https://diabetescoreupdate.libsyn.com/associations-between-glp-1-receptor-agonists-and-ischemic-optic-neuropathy-tirzepetide-vs-dulaglutide-or-semaglutide-on-major-cardiovascular-events-in-t2d-and-more
Audio file: https://traffic.libsyn.com/secure/diabetescoreupdate/Diabetes_Core_Update_May_2026.mp3?dest-id=159994
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/doc-updates-200053/episodes/associations-between-glp-1-receptor-agonists-and-ischemic-optic-neuropathy-tirzepetide-vs-dulaglutide-or-semaglutide-on-major-cardiovascular-events-in-t2d-and-more
Duration seconds: 2219

## Resource

Welcome to the latest episode (May 2026) of Diabetes Core Update , where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month, they discuss: Marston NA, Bohula EA, Bhatia AK, et al. " Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial ." JAMA. 2026;335(16):1400–1407. doi:10.1001/jama.2026.3277 Lee YJ, Lee SJ, Kim JW, et al. " Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease ." N Engl J Med 2026;394:1365-1375. doi:10.1056/NEJMoa2600283 Nissen SE, Wolski K, D'Alessio D, et al. " Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial ." JAMA Cardiol. Published online March 28, 2026. doi:10.1001/jamacardio.2026.0767 Moura FA, et al. " Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis ." Diabetes Care. 2026;49(5):724–729. doi.org/10.2337/dc25-1238 Ostrominski JW, Ortega-Montiel J, et al. " Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations ." Diabetes Care. 2026;49(5):808–817 doi.org/10.2337/dc25-3063 Nicole Napoli, " Shingles Vaccine Drastically Cuts Risk of Serious Cardiac Events ." The American College of Cardiology. March 17, 2026 https://www.acc.org/About-ACC/Press-Releases/2026/03/16/19/33/Shingles-Vaccine-Drastically-Cuts-Risk-of-Serious-Cardiac-Events For information about the American Diabetes Association's scholarly journals,…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/doc-updates-200053/episodes/associations-between-glp-1-receptor-agonists-and-ischemic-optic-neuropathy-tirzepetide-vs-dulaglutide-or-semaglutide-on-major-cardiovascular-events-in-t2d-and-more/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/doc-updates-200053/associations-between-glp-1-receptor-agonists-and-ischemic-optic-neuropathy-tirzepetide-vs-dulaglutide-or-semaglutide-on-major-cardiovascular-events-in-t2d-and-more.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.